Presenter Status
Resident/Psychology Intern
Abstract Type
Research
Primary Mentor
Bridgette Jones, MD
Start Date
5-5-2022 12:45 PM
End Date
5-5-2022 1:00 PM
Presentation Type
Oral Presentation
Description
Watch recording of live presentation.
Rationale: Black/African American and Hispanic people in the United States are disproportionately impacted by asthma with increased prevalence, morbidity, and mortality. However, these groups are often under-represented in asthma clinical and translational research studies which is a barrier to achieving health equity. We describe the racial/ethnic makeup of participants included in clinical trials which informed the recent 2020 National Heart, Lung, and Blood Institute(NHLBI) asthma management guidelines focused update.
Methods: We identified clinical trials included within the 2020 NHLBI asthma management guidelines focused update. We determined the frequency (%) of studies reporting study participant racial/ethnic demographics and the % of identified racial/ethnic groups among those studies.
Results: Racial demographics were reported in only 36% (16/45) of trials. Among trial conducted only in the United States (US) (n=6) all reported racial/ethnic demographics but two of the trials only reported the white racial group. Among all trials reporting race/ethnicity the majority of participants identified as White (n=31675) 70.8% followed by Black (n=4653) 10.4% and Hispanic (n=91) 0.2% (American Indian/Alaskan Native/ Native Hawaiian/Pacific Islander and Other were 2.6% and 6.1% of participants respectively). Demographic representation varied between US and non-US trials and between pediatric and non-pediatric studies.
Conclusions: Less than half of clinical trials reported race/ethnicity data. White participants were generally over-represented and Black and Hispanic populations were under-represented within trials. Intentional inclusion efforts are needed to increase the racial/ethnic diversity of trials informing national asthma guidelines and these factors should also be considered when developing such guidelines.
MeSH Keywords
racial makeup of asthma clinical trials
Additional Files
The Racial and Ethnic Makeup of the Asthma Clinical Trials informing the 2020 NHLBI asthma guidelines update.pdf (137 kB)Abstract
The Racial and Ethnic Makeup of the Asthma Clinical Trials informing the 2020 NHLBI asthma guidelines update
Watch recording of live presentation.
Rationale: Black/African American and Hispanic people in the United States are disproportionately impacted by asthma with increased prevalence, morbidity, and mortality. However, these groups are often under-represented in asthma clinical and translational research studies which is a barrier to achieving health equity. We describe the racial/ethnic makeup of participants included in clinical trials which informed the recent 2020 National Heart, Lung, and Blood Institute(NHLBI) asthma management guidelines focused update.
Methods: We identified clinical trials included within the 2020 NHLBI asthma management guidelines focused update. We determined the frequency (%) of studies reporting study participant racial/ethnic demographics and the % of identified racial/ethnic groups among those studies.
Results: Racial demographics were reported in only 36% (16/45) of trials. Among trial conducted only in the United States (US) (n=6) all reported racial/ethnic demographics but two of the trials only reported the white racial group. Among all trials reporting race/ethnicity the majority of participants identified as White (n=31675) 70.8% followed by Black (n=4653) 10.4% and Hispanic (n=91) 0.2% (American Indian/Alaskan Native/ Native Hawaiian/Pacific Islander and Other were 2.6% and 6.1% of participants respectively). Demographic representation varied between US and non-US trials and between pediatric and non-pediatric studies.
Conclusions: Less than half of clinical trials reported race/ethnicity data. White participants were generally over-represented and Black and Hispanic populations were under-represented within trials. Intentional inclusion efforts are needed to increase the racial/ethnic diversity of trials informing national asthma guidelines and these factors should also be considered when developing such guidelines.
